Optimization of Radiation Protection Through Genomic Analyses

NCT06253338 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital, Essen

Phase

Not applicable

Started

2024-06-01

Last updated

2024-09-27

Condition(s) studied

DNACancerRadiation

Investigational drug(s) / intervention(s)

genomic alterations

genomic alterations: Alteration of the genome under radiotherapy

Study summary

The long-term goal is to define "signatures" in the form of genomic changes through sequence analyses of genomic DNA using modern Next Generation Sequencing (NGS) methods, which

1. determine the radiation exposure of humans.
2. provide information about the exposure (dose).
3. determine the radiation quality.
4. predict the repair capacity and radiation resistance of an individual.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: ECOG 0/1 no prior treatment no prior cancer diagnosis thoracic or head and neck cancer Exclusion Criteria: prior treatment (chemotherapy, radiotherapy, etc.) prior cancer diagnosis

Primary outcome measure(s)

Alteration of the genome under radiotherapy — 5 years
Radiotherapy of patients, quantitative tissue sampling, cell culture survival rate and mitotic index after predifined radiation treatment, Incidence of the sample and percentage

Trial sites (1)

Facility	City	Region	Status
Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West	Essen	Germany / NRW	Recruiting

More University Hospital, Essen trials in Germany

Tourniquet-Test in HHT Active, not recruiting

Essen Coronary Artery Disease Registry Recruiting

Essen Amyloidosis Registry Recruiting

Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma Recruiting

Body Donation in HHT Recruiting

Other trials for the same condition

Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases Recruiting

Pan Tumor Rollover Study Recruiting

Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries. Recruiting

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor Active, not recruiting

Multi-professional Care Pathway and Network for the Promotion of Needs-oriented, Resident-oriented Exercise Therapy for Oncological Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06253338 on ClinicalTrials.gov ↗ ← All trials in Germany